Host-directed antiviral therapeutics and the NIAID research agenda: an underexplored frontier

Host-directed antiviral therapeutics and the NIAID research agenda: an underexplored frontier

Saved in:

Bibliographic Details
Main Authors:	David E. Martin, Ralph A. Tripp
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Virology
Subjects:	host-directed therapies direct acting anti-viral drugs NIAID influenza coronavirus (CoV) pandemic preparedness
Online Access:	https://www.frontiersin.org/articles/10.3389/fviro.2024.1458112/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies
by: Zorana Ferjancic, et al.
Published: (2024-12-01)

Is Avian influenza virus still threatening humans? Preventative measures and treatment
by: Jacek Fordymacki, et al.
Published: (2025-01-01)

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies
by: Palaniyandi Muthukutty, et al.
Published: (2024-10-01)

Problematic issues of the effectiveness of treatment of patients with chronic viral hepatitis C according to the State program and the ways of their solution.
by: L. R. Shostakovych-Koretska, et al.
Published: (2018-11-01)

Lessons learned and real-world insights from implementing neutralizing monoclonal antibody programs for treatment of COVID-19
by: Nalini Ambrose, et al.
Published: (2024-01-01)

Molecular diagnostics using the QIAstat-Dx syndromic device for covering avian influenza pandemic preparedness
by: Luis Peñarrubia, et al.
Published: (2024-12-01)

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination
by: Dorota Zarębska-Michaluk, et al.
Published: (2024-10-01)

Influenza Virus Surveillance from the 1918 Influenza Pandemic to the 2020 Coronavirus Pandemic in New York State, USA
by: Kay L. Escuyer, et al.
Published: (2024-12-01)

Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis
by: Sarah R. Donaldson, et al.
Published: (2025-01-01)

Clinical Characteristics and Outcomes of Hospitalized AECOPDs Secondary to SARS-CoV-2 versus Other Respiratory Viruses
by: Chhor L, et al.
Published: (2024-11-01)

An ODEs multiscale model with cell proliferation for hepatitis C virus infection treated with direct acting antiviral agents
by: Hesham A. Elkaranshawy, et al.
Published: (2024-12-01)

Pragmatic Analysis of Searle’s Directive Acts Types in “Get Out Movie”
by: Fanny Virginia, et al.
Published: (2022-12-01)

The application and prospects of antimicrobial peptides in antiviral therapy
by: Fei Yang, et al.
Published: (2024-12-01)

Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review
by: Ioana Adela Ratiu, et al.
Published: (2024-12-01)

THE DARK SIDE OF THE COVID-19 TREATMENTS ON MYCOBACTERIUM TUBERCULOSIS INFECTION
by: Flavio De Maio, et al.
Published: (2022-02-01)

THE RESPONDS OF DIRECTIVE SPEECH ACTS BY THE CHARACTERS IN JACK THE GIANT SLYER (2013) MOVIE
by: Ruminda Ruminda
Published: (2018-09-01)

Public health system in post-pandemic Sierra Leone: a scoping review
by: Jia Bainga Kangbai, et al.
Published: (2024-12-01)

Exploiting the Achilles’ Heel of Viral RNA Processing to Develop Novel Antivirals
by: Ali Zahedi Amiri, et al.
Published: (2024-12-01)

The PA-X host shutoff site 100 V exerts a contrary effect on viral fitness of the highly pathogenic H7N9 influenza A virus in mice and chickens
by: Xia Chen, et al.
Published: (2025-12-01)

Value of autotaxin as a serum marker for liver fibrosis in chronic HCV infected patients receiving direct-acting antiviral therapy
by: Ahmed Moustafa, et al.
Published: (2024-08-01)

Predictors of liver fibrosis changes assessed by paired liver biopsies in chronic hepatitis C patients treated with direct-acting antivirals
by: Ming-Han Hsieh, et al.
Published: (2024-12-01)

Self-reported experience in patients treated with Hepatitis C direct acting antivirals
by: Irene Cañamares Orbis, et al.
Published: (2016-12-01)

Potential antiviral activity of rhamnocitrin against influenza virus H3N2 by inhibiting cGAS/STING pathway in vitro
by: Zexing Chen, et al.
Published: (2024-11-01)

Editorial: How RSV outsmarts the host
by: Stephania A. Cormier, et al.
Published: (2024-12-01)

Pharmacological interactions in novel oral anticoagulants, statins, and hypertension drugs in patients treated with direct-acting antivirals for hepatitis C: a Delphi Consensus project
by: Ivan Gentile, et al.
Published: (2024-11-01)

Eco-evolutionary dynamics of adapting pathogens and host immunity
by: Pierre Barrat-Charlaix, et al.
Published: (2024-12-01)

Investigating SARS-CoV-2 Neutralising Antibody Response in Sheep
by: Milena Samojlović, et al.
Published: (2024-12-01)

Influenza B Pneumonia with Pneumomediastinum, Subcutaneous Emphysema and Encephalitis. A Rare Presentation
by: Prachi Singh, et al.
Published: (2025-01-01)

Characteristics of Patients in Intensive Care Units with the Diagnosis of COVID-19: Retrospective Analysis
by: Zeynel Abidin Erbesler, et al.
Published: (2024-12-01)

Response to Interferon-Free Direct Antivirals (DAAS) Treatment in HCV-Related Subcutaneous Lipoma-Like Marginal Zone B-Cell Lymphoma
by: Maria Lucia De Luca, et al.
Published: (2019-08-01)

Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents
by: Zhang Y, et al.
Published: (2025-01-01)

Evidence-Based Guidance for One Health Preparedness, Prevention, and Response Strategies to Marburg Virus Disease Outbreaks
by: Claude Mambo Muvunyi, et al.
Published: (2024-12-01)

Characterisation of specific responses to three models of viral antigens in immunocompetent older adults
by: Beatriz Rioseras, et al.
Published: (2024-12-01)

SARS-CoV-2 Assembly: Gaining Infectivity and Beyond
by: Harshita Katiyar, et al.
Published: (2024-10-01)

Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses
by: Harry Ridgway, et al.
Published: (2024-11-01)

Preparedness, prevention and control related to zoonotic avian influenza
by: EFSA Panel on Animal Health and Animal Welfare (AHAW), et al.
Published: (2025-01-01)

New drugs in the treatment of chronic hepatitis C
by: R. Jimenez Galan, et al.
Published: (2014-04-01)

Unveiling the Role of TMPRSS2 in the Proteolytic Activation of Pandemic and Zoonotic Influenza Viruses and Coronaviruses in Human Airway Cells
by: Marie Schwerdtner, et al.
Published: (2024-11-01)

Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
by: Carlo Smirne, et al.
Published: (2024-12-01)

Global avian influenza situation (2019–2022). Host range expansion asevidence of high pathogenicity avian influenza virus evolution
by: M. V. Zhiltsova, et al.
Published: (2023-12-01)